Skip to main content

Health condition · Clinically reviewed

Gallbladder cancer, radical surgery, systemic therapy and specialist hepatobiliary care.

Rare, often late and disproportionately aggressive - but modern UK care combines specialist-commissioned surgery, chemotherapy, immunotherapy and molecular profiling to change the picture.

Jump to treatment
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why trust this guide

  • 01

    Clinically reviewed

    Written by our editorial team and reviewed by a registered UK clinician before publication.

  • 02

    Sourced from guidance

    Checked against NCCN, BSG and peer-reviewed hepatobiliary sources you can see at the end.

  • 03

    Current for 2026

    Reflects modern UK practice including specialist-commissioned hepatobiliary surgery, KEYNOTE-966 and molecular profiling.

Key facts

Gallbladder cancer at a glance.

The essentials, in plain English - what it is, who it affects, and how it is treated in specialist UK centres today.

  • What it is

    A rare and aggressive cancer arising from the gallbladder wall - most often adenocarcinoma, frequently found late or incidentally.

  • How common

    Around 700 new UK cases each year - uncommon but disproportionately fatal because of late presentation.

  • Who gets it

    Peak incidence in the 60s to 80s, women affected 2 to 3 times more often than men.

  • Main driver

    Long-standing gallstones and chronic cholecystitis - see our guide at /conditions/gallstones/ for the underlying condition.

  • Curative option

    Surgery is the only curative treatment - radical cholecystectomy with liver resection at a specialist-commissioned hepatobiliary centre.

  • Systemic therapy

    Cisplatin plus gemcitabine remains first-line - increasingly combined with immunotherapy (pembrolizumab, durvalumab).

Why this guide matters

Rare, aggressive, and treated at specialist centres.

Gallbladder cancer is uncommon but disproportionately serious. The three points below shape everything else on this page.

  • Presentation is often late

    Symptoms are non-specific and overlap with gallstones - many people present with weight loss, jaundice or a mass rather than early pain alone.

  • Surgery is the only cure

    Radical cholecystectomy with liver resection at a specialist-commissioned hepatobiliary centre is the only route to long-term cure.

  • Systemic care is expanding

    Cisplatin and gemcitabine plus immunotherapy - and molecular profiling for IDH1, FGFR2 and HER2 - are opening real options for advanced disease.

How the diagnosis is made

From first symptom to a clear plan.

The steps a UK GP and specialist hepatobiliary team will normally follow, in order - so you know what to expect and why.

  1. 01

    Assessing

    History and risk factors

    A structured history covering gallstones, cholecystitis, polyps, biliary anomalies and family or ethnic risk.

  2. 02

    Assessing

    Examination

    Abdominal exam looking for right-upper-quadrant tenderness, hepatomegaly or a palpable mass - Courvoisier’s sign is a red flag.

  3. 03

    Assessing

    Bloods

    Full blood count, liver function tests and tumour markers CA 19-9 and CEA to support the picture.

  4. 04

    Confirming

    Ultrasound first

    Abdominal ultrasound is usually the first imaging - looks at wall thickening, mass and biliary dilatation.

  5. 05

    Confirming

    CT, MRI and MRCP

    Cross-sectional imaging stages the disease and maps the biliary tree - specialist-commissioned hepatobiliary review.

  6. 06

    Confirming

    PET-CT and ERCP as needed

    PET-CT for occult disease and ERCP with stenting where jaundice needs relief - specialist-led.

  7. 07

    Planning

    Staging laparoscopy and MDT

    Laparoscopy for T2 to T3 disease to detect peritoneal spread - decisions made at a specialist-commissioned hepatobiliary MDT.

Typical timeline: first imaging to a specialist MDT plan in a small number of weeks.

Symptoms

What gallbladder cancer actually looks like.

Vague and non-specific early on - abdominal pain, weight loss and appetite loss. Jaundice, hepatomegaly and Courvoisier’s sign appear later.

  • Right upper quadrant pain

    A dull, persistent ache under the right ribs - often mistaken for gallstone or ulcer symptoms.

  • Unintentional weight loss

    Steady loss without dieting - a common systemic feature of biliary and pancreatic malignancy.

  • Anorexia and early satiety

    Loss of appetite or feeling full quickly - a subtle but important warning sign.

  • Jaundice

    Yellowing of skin and eyes, dark urine and pale stools - usually a late feature suggesting biliary obstruction.

  • Hepatomegaly

    An enlarged liver on examination - may reflect direct invasion or metastatic spread.

  • Palpable mass

    A firm mass in the right upper quadrant - sometimes the gallbladder itself, sometimes local nodal disease.

  • Incidental finding

    Around 1 to 3 per cent of cholecystectomies for gallstones reveal an unexpected early cancer at histology.

  • Red flag - Courvoisier’s law

    Painless jaundice with a palpable gallbladder is malignancy until proven otherwise - urgent specialist referral.

Treatment

How gallbladder cancer is treated in the UK.

Radical surgery where possible, cisplatin and gemcitabine as first-line systemic therapy, and immunotherapy plus targeted agents for advanced disease.

  • Radical cholecystectomy

    The only curative option - gallbladder removal with segments IVb and V liver resection and regional lymphadenectomy at a specialist-commissioned hepatobiliary centre.

  • Re-operation after incidental cancer

    For T1b and above found unexpectedly on a routine cholecystectomy - completion resection at a specialist centre improves outcomes.

  • Cisplatin and gemcitabine

    First-line chemotherapy for advanced or unresectable disease - specialist medical oncology.

  • Immunotherapy

    Pembrolizumab (KEYNOTE-966) and durvalumab (TOPAZ-1) added to chemotherapy - specialist-commissioned. See /treatments/immunotherapy-checkpoint-clinic/.

  • Targeted therapy

    IDH1 inhibitors (ivosidenib), FGFR2 fusion drugs (pemigatinib, futibatinib) and HER2-directed regimens where molecular profiling supports it - see /treatments/tumour-molecular-profiling/.

  • Biliary drainage

    ERCP-guided stenting or percutaneous transhepatic drainage for obstructive jaundice - improves comfort and liver function.

  • Palliative symptom control

    Celiac plexus block for pain, antiemetics and structured symptom care through specialist palliative teams and Macmillan.

  • Clinical trials and support

    AMMF and Cholangiocarcinoma UK signpost trials and support - specialist-commissioned biliary trial access at UK centres.

What this guide is based on

The sources behind every claim on this page.

International hepatobiliary guidance, UK specialist society standards and pivotal trials, current at the time of last review.

Key references

Guidelines and standards we relied on.

A quiet reminder

This guide is for information, not medical advice.

Your GP, hepatobiliary surgeon and oncology team know your situation and can tell you which parts apply to you. If in doubt, get seen.

  • NCCN. Clinical Practice Guidelines in Oncology - Biliary Tract Cancers.

  • British Society of Gastroenterology (BSG). Guidelines on the management of pancreatobiliary disease.

  • KEYNOTE-966 trial - pembrolizumab plus gemcitabine and cisplatin in biliary tract cancer.

  • TOPAZ-1 trial - durvalumab plus gemcitabine and cisplatin in biliary tract cancer.

  • AMMF (The Cholangiocarcinoma Charity) and Cholangiocarcinoma UK patient resources.

Red flags

When it needs urgent specialist attention.

These are the features and settings that shift the picture from benign biliary disease to a suspected malignancy - and where a hepatobiliary specialist is needed.

  • Courvoisier’s sign

    Painless jaundice with a palpable gallbladder is malignancy until proven otherwise - urgent specialist assessment.

  • Progressive obstructive jaundice

    Deepening yellow, dark urine and pale stools warrant same-week hepatobiliary imaging and ERCP planning.

  • Porcelain gallbladder

    Calcification of the gallbladder wall is associated with cancer risk - specialist review and often surgery.

  • Gallbladder polyps over 1 cm

    Larger polyps carry meaningful malignant potential - specialist surgical review is the safe default.

  • Weight loss with biliary symptoms

    Any unexplained weight loss alongside abdominal or biliary symptoms deserves urgent cross-sectional imaging.

  • Incidental T1b or higher

    Cancer found unexpectedly at cholecystectomy needs prompt re-referral to a specialist hepatobiliary MDT.

  • Chronic Salmonella carriage

    Long-standing typhoid carriage is a recognised risk factor - a low threshold for imaging is warranted.

  • Primary sclerosing cholangitis

    People with PSC have raised biliary cancer risk - specialist surveillance protocols apply.

  • High-risk ethnic background

    Native American, Chilean and South Asian populations carry higher baseline risk - factor into clinical thresholds.

Living with it

A serious diagnosis, with real support around it.

Four things that make the biggest difference day to day - the specialist team, biliary-specific charities, protecting nutrition, and honest conversations about what matters.

A quiet reminder

You are not managing this on your own.

Specialist nurses, clinical nurse specialists and Macmillan sit alongside the MDT - a phone call away between clinics.

  1. 01 Team

    Lean on the MDT

    A specialist-commissioned hepatobiliary MDT co-ordinates surgery, oncology, radiology, pathology and palliative care so nothing falls between chairs.

  2. 02 Support

    Use AMMF and Macmillan

    AMMF and Cholangiocarcinoma UK offer biliary-specific information and community. Macmillan supports the practical, financial and emotional load.

  3. 03 Nutrition

    Protect weight and strength

    Biliary obstruction and chemotherapy both erode nutrition - specialist dietetic input and enzyme supplementation help preserve function.

  4. 04 Planning

    Talk about what matters

    Early conversations about goals, preferences and advance care planning make later decisions easier and more personal.

Frequently asked

Everything we get asked about gallbladder cancer.

Quick answers on diagnosis, radical surgery, chemotherapy, immunotherapy and biliary drainage.

  • What is gallbladder cancer?

    A malignant tumour arising from the gallbladder wall, most often adenocarcinoma. It is uncommon but aggressive, and is often diagnosed at an advanced stage because early symptoms are vague and overlap with benign gallstone disease.

  • What causes gallbladder cancer?

    Long-standing gallstones and chronic cholecystitis are the main drivers. Other risk factors include obesity, porcelain gallbladder, gallbladder polyps larger than 1 cm, primary sclerosing cholangitis, chronic Salmonella carriage, congenital biliary anomalies and higher-risk ethnic backgrounds (Native American, Chilean, South Asian).

  • How is it diagnosed?

    Assessment starts with history, examination and bloods including LFTs, CA 19-9 and CEA. Ultrasound is usually first, followed by CT, MRI and MRCP for staging. PET-CT, ERCP and staging laparoscopy are used selectively at specialist-commissioned hepatobiliary centres, with decisions made at an MDT.

  • Can gallbladder cancer be cured?

    Surgery is the only curative option. Radical cholecystectomy with resection of liver segments IVb and V and regional lymphadenectomy is performed at specialist-commissioned hepatobiliary centres. Cancer found incidentally at cholecystectomy (T1b or above) often needs a second, more radical operation.

  • What treatments are used when surgery is not possible?

    First-line chemotherapy is cisplatin and gemcitabine, increasingly combined with immunotherapy (pembrolizumab from KEYNOTE-966, durvalumab from TOPAZ-1). Targeted therapies including IDH1 inhibitors, FGFR2 fusion drugs and HER2-directed regimens are considered when molecular profiling supports them.

  • How is jaundice managed?

    Obstructive jaundice is relieved with biliary drainage - ERCP-guided stenting where possible, or percutaneous transhepatic cholangiography. Alongside symptom control, this improves liver function and quality of life and often makes systemic therapy feasible.

Related content

Keep reading.

Pulse Healthcare concierge

Send us your enquiry

A concierge service for UK private healthcare. We match you with the best vetted clinics and consultants in our network - they then contact you directly.

So we can match you to the right clinician close to you.

We reply to every enquiry within 24 hours (Mon–Fri). Confidential - your details are never shared outside our vetted consultant network.